Expansion of R&D and Product Pipeline
First written in FY2016. 23 of 34 entries say "Restated". Latest entry: FY2026.
5 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「R&D expenses for the current consolidated fiscal year were ¥76.9 billion, representing 6.8% of revenue.」
R&D expenses were ¥76.9 billion, representing 6.8% of revenue. The company disclosed progress in its product and technology pipelines, including FDA 510(k) clearance for OPUSWAVE, domestic approval for Kanshas, MDR certification for CDI OneView, and the launch of Surflow Midela. - FY2025AdvancedAnnual report
「R&D expenses for the current consolidated fiscal year were ¥74.2 billion, representing 7.2% of revenue.」
R&D expenses were ¥74.2 billion, representing 7.2% of revenue. The company reported specific progress in its product and technology pipelines, including MDR approval for Ultimaster, the start of sales of Rachetta, and a partnership related to cell therapy using Quantum Flex. - FY2025-H1RestatedAnnual report
「The Group's R&D activities totaled ¥36.8 billion during the current interim consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company recorded R&D expenses of ¥36.8 billion but explained that there were no material changes in the status of its R&D activities. - FY2024AdvancedAnnual report
「R&D expenses for the current consolidated fiscal year were ¥69.1 billion, representing 7.5% of revenue. In the Cardiovascular Company, the company obtained CE marking for the drug-eluting coronary stent Ultimaster Nagomi, confirming compliance with European Union (EU) safety requirements, and began sales in the European market.」
R&D expenses were ¥69.1 billion, representing 7.5% of revenue. The company reported specific progress in its product pipeline, including CE marking for Ultimaster Nagomi and the start of sales in Europe, the publication of clinical data for WEB, and US approval for the RelayPro indication. - FY2024-Q3RestatedAnnual report
「The Group's R&D activities totaled ¥49.1 billion during the cumulative first three quarters of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company recorded R&D expenses of ¥49.1 billion but explained that there were no material changes in the status of its R&D activities. - FY2024-Q2RestatedAnnual report
「The Group's R&D activities totaled ¥31.8 billion during the cumulative second quarter of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
Cumulative R&D expenses for FY2024-Q2 were ¥31.8 billion. The company continued to explain that there were no material changes in the status of its R&D activities. - FY2024-Q1RestatedAnnual report
「The Group's R&D activities totaled ¥15.4 billion during the cumulative first quarter of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company recorded R&D expenses of ¥15.4 billion and explained that there were no material changes in the status of its R&D activities. - FY2023AdvancedAnnual report
「R&D expenses for the current consolidated fiscal year were ¥61.6 billion, representing 7.5% of revenue.」
R&D expenses were ¥61.6 billion, representing 7.5% of revenue. In addition to developing new products in the Cardiovascular, Medical Care Solutions, and Blood and Cell Technologies businesses, the company introduced technology-focused Centers of Excellence. - FY2023-Q3RestatedAnnual report
「The Group's R&D activities totaled ¥45.6 billion during the cumulative first three quarters of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company recorded R&D expenses of ¥45.6 billion and explained that there were no material changes in the status of its R&D activities. - FY2023-Q2RestatedAnnual report
「The Group's R&D activities totaled ¥29.7 billion during the cumulative second quarter of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company recorded R&D expenses of ¥29.7 billion but explained that there were no material changes in the status of its R&D activities. - FY2023-Q1RestatedAnnual report
「The Group's R&D activities totaled ¥14.1 billion during the cumulative first quarter of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company explained that it recorded R&D expenses of ¥14.1 billion and that there were no material changes in the status of its R&D activities. - FY2022AdvancedAnnual report
「R&D expenses for the current consolidated fiscal year were ¥51.8 billion, representing 7.4% of revenue.」
R&D expenses were ¥51.8 billion, representing 7.4% of revenue. In addition to launching new products, the company proceeded with preparations to introduce Centers of Excellence covering 5 technology areas. - FY2022-Q3RestatedAnnual report
「The Group's R&D activities totaled ¥37.5 billion during the cumulative first three quarters of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company explained that cumulative R&D expenses for FY2022-Q3 were ¥37.5 billion and that there were no material changes in the status of its R&D activities. - FY2022-Q2RestatedAnnual report
「The Group's R&D activities totaled ¥24.7 billion during the cumulative second quarter of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company explained that it recorded R&D expenses of ¥24.7 billion and that there were no material changes in the status of its R&D activities. - FY2022-Q1RestatedAnnual report
「The Group's R&D activities totaled ¥11.7 billion during the cumulative first quarter of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company explained that R&D expenses were ¥11.7 billion in FY2022-Q1 and that there were no material changes in the status of its R&D activities. - FY2021AdvancedAnnual report
「R&D expenses for the current consolidated fiscal year were ¥49.1 billion, representing 8.0% of revenue.」
R&D expenses were ¥49.1 billion, representing 8.0% of revenue. The company proceeded with Renzan clinical research, the launches of FRED, CASPER Rx and Woven EndoBridge, and the development and approval of FN Syringe and Medisafe With, among other products. - FY2021-Q3RestatedAnnual report
「The Group's R&D activities totaled ¥35.9 billion during the cumulative first three quarters of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company reported R&D expenses of ¥35.9 billion for the cumulative first three quarters of the current consolidated fiscal year and no material changes in the status of its R&D activities. - FY2021-Q1RestatedAnnual report
「The Group's R&D activities totaled ¥11.2 billion during the cumulative first quarter of the current consolidated fiscal year. There were no material changes in the status of the Group's R&D activities during the period.」
The company explained that R&D expenses were ¥11.2 billion in FY2021-Q1 and that there were no material changes in the status of its R&D activities. - FY2020AdvancedAnnual report
「Research and development expenses for the consolidated fiscal year were ¥50.6 billion, or 8.0% of revenue.」
R&D expenses were ¥50.6 billion, representing 8.0% of revenue. In addition to developing and rolling out Misago, SOFIAFLOW Plus, WEB, FRED, hospital IT integration products and FINIA, the company proceeded with investments of up to US$25 million each in two US venture capital funds and strengthened its development centers. - FY2020-Q3RestatedAnnual report
「The Group's research and development expenditure for the first nine months of the fiscal year was ¥37.0 billion.」
The company reported research and development expenses of ¥37.0 billion for the first nine months of the fiscal year and stated that there had been no material changes in research and development activities. - FY2020-Q2RestatedAnnual report
「The Group's research and development expenditure for the first six months of the fiscal year was ¥24.3 billion.」
The company reported research and development expenses of ¥24.3 billion for the first six months of the fiscal year and stated that there had been no material changes in research and development activities. - FY2019AdvancedAnnual report
「Research and development expenses for the consolidated fiscal year were ¥47.7 billion, or 8.0% of revenue.」
The company reported research and development expenses of ¥47.7 billion, or 8.0% of revenue, and described progress in the product pipeline, including US marketing approval for WEB, Japanese approval for SOFIAFLOW Plus, and the launch of Ultimaster Tansei and other products. - FY2019-Q3RestatedAnnual report
「The Group's research and development expenditure for the first nine months of the fiscal year was ¥36.0 billion. There were no material changes in the status of the Terumo Group's research and development activities during the first nine months of the fiscal year.」
The company reported research and development expenses of ¥36.0 billion for the first nine months of the fiscal year and stated that there had been no material changes in research and development activities. - FY2019-Q2RestatedAnnual report
「The Group's research and development expenditure for the first six months of the fiscal year was ¥23.8 billion. There were no material changes in the status of the Terumo Group's research and development activities during the first six months of the fiscal year.」
The company reported research and development expenses of ¥23.8 billion for the first six months of the fiscal year and stated that there had been no material changes in research and development activities. - FY2019-Q1RestatedAnnual report
「The Group's research and development expenditure for the first quarter of the fiscal year was ¥11.3 billion. There were no material changes in the status of the Terumo Group's research and development activities during the first quarter of the fiscal year.」
The company reported research and development expenses of ¥11.3 billion for the first quarter and stated that there had been no material changes in research and development activities. - FY2018AdvancedAnnual report
「Research and development expenses for the consolidated fiscal year were ¥41.3 billion, or 7.0% of revenue. In the Cardiovascular Company, the company advanced development of the next-generation version of the existing drug-eluting coronary stent “Ultimaster” to address more complex treatments for angina and myocardial infarction.」
The company recorded research and development expenses of ¥41.3 billion, or 7.0% of revenue, and advanced development, regulatory approval, and preparations for the launch of the next-generation Ultimaster, artificial lungs, drug-coated balloon catheters, Medisafe With, and other products. - FY2018-Q3RestatedAnnual report
「The Group's research and development expenditure for the first nine months of the fiscal year was ¥28.7 billion. There were no material changes in the status of the Terumo Group's research and development activities during the first nine months of the fiscal year.」
The company reported research and development expenses of ¥28.7 billion for the first nine months of the fiscal year and stated that there had been no material changes in research and development activities. - FY2018-Q2RestatedAnnual report
「The Group's research and development expenditure for the first six months of the fiscal year was ¥18.0 billion. There were no material changes in the status of the Terumo Group's research and development activities during the first six months of the fiscal year.」
The company reported research and development expenses of ¥18.0 billion for the first six months of the fiscal year and stated that there had been no material changes in research and development activities. - FY2018-Q1RestatedAnnual report
「The group-wide amount spent on R&D activities during the cumulative first quarter of the current consolidated fiscal year was ¥8.5 billion. There were no material changes in the status of our group's R&D activities during the cumulative first quarter of the current consolidated fiscal year.」
The company reported research and development expenses of ¥8.5 billion for the quarter and stated that there had been no material changes in research and development activities. - FY2017AdvancedAnnual report
「Research and development expenses for the consolidated fiscal year were ¥33.7 billion, or 6.6% of net sales. In the Cardiovascular Company, the company expanded the Ultimaster lineup in Japan, beginning sales of products with a 4 mm stent diameter in August 2016 and a 2.25 mm diameter in February 2017. In February 2017, it also began full-scale sales in Japan of the VISICUBE ultrasound diagnostic imaging system and the AltaView intravascular ultrasound catheter.」
The company recorded research and development expenses of ¥33.7 billion, or 6.6% of net sales, and reported progress in the product pipeline, including expansion of the Ultimaster lineup and the launch of full-scale sales of VISICUBE and AltaView. - FY2017-Q3RestatedAnnual report
「The Group's research and development expenditure for the first nine months of the fiscal year was ¥24.5 billion.」
The company reported research and development expenditure of ¥24.5 billion for the first nine months of the fiscal year and stated that there had been no material changes in its activities. - FY2017-Q2RestatedAnnual report
「The Group's research and development expenditure for the first six months of the fiscal year was ¥16.3 billion.」
The company reported research and development expenses of ¥16.3 billion for the first six months of the fiscal year and stated that there had been no material changes in research and development activities. - FY2017-Q1RestatedAnnual report
「The Group's research and development expenditure for the first quarter of the fiscal year was ¥8.1 billion.」
The company reported research and development expenditure of ¥8.1 billion for the first quarter and stated that there had been no material changes in research and development activities. - FY2016First statedAnnual report
「To further enhance our global competitive advantage, we will expand our product pipeline, explore growth opportunities primarily in areas adjacent to our existing businesses, and invest in promising technologies and products.」
Research and development expenses for the period were ¥33.1 billion, or 6.3% of net sales: ¥16.4 billion in cardiovascular, ¥3.8 billion in hospital, ¥7.9 billion in blood systems, and ¥4.8 billion in basic research.